Analyst Coverage

The following organisations provide research coverage on Pharmaxis: 

Bell Potter logo1

Bell Potter Securities Limited

Analyst: Tanushree Jain (tnjain@bellpotter.com.au)

Bell Potter initiated coverage on 8 December 2017.

For copies of current reports contact Bell Potter.

30 April 2018

Interim data from Phase 1 LOXL-2 program strengthen partnering prospects

16 February 2018 1H18 Results - no material change from unaudited results released earlier
1 February 2018

Good clinical and partnering progress on LOXL-2 asset

11 January 2018

BI milestone strengthens balance sheet, LOXL-2 moves into the clinic

8 December 2017

Emerging as a key player in multi-billion dollar NASH market

Bioshares5

Bioshares

Editors: David Blake and Mark Pachacz (info@bioshares.com.au)

Read Bioshares most recent reports:

13 August 2018 Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal
20 July 2018 Interview with Dr Kathleen Metters
8 May 2018

Pharmaxis – a drug developer with a deal making record

5 February 2018 A busy year for Pharmaxis – multiple trial readouts ahead
8 September 2017

Pharmaxis – Boehringer selects diabetic retinopathy as second indication

4 September 2017

Pharmaxis' partner starts phase II NASH trial

24 March 2017

Three share price drivers for Pharmaxis

28 October 2016 Pharmaxis. All attention on NASH for Pharmaxis